Real-Life Effectiveness and Safety of Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: A Single-Center 16-Week Study

• DOI: 10.1007/s13555-022-00882-z
• Publication Date: 2023-01-09T03:03:36Z
• Authors: Luigi Gargiulo; Luciano Ibba; Andrea Cortese; Jessica Avagliano; Mario Valenti; Antonio Costanzo; Alessandra Narcisi
• Keywords: Single Center; Center (category theory)

The treatment of severe atopic dermatitis (AD) includes cyclosporine and recently approved biologics small molecules. Among these, upadacitinib is a selective inhibitor Janus kinase 1, for the AD in adolescents/adults. Upadacitinib has shown efficacy safety several phase 3 clinical trials, but data on real-life patients are still lacking. We conducted retrospective observational study to evaluate effectiveness up week 16 cohort both bio-naïve bio-experienced patients. This was carried out by analyzing database records an Italian referral hospital. Thirty-eight were included this study, 35 completed weeks treatment. At 16, patients, percentages Eczema Area Severity Index (EASI) 50, EASI 75, 90 100 responses 94.29, 91.43, 74.29, 60%, respectively. A decrease at least 4 points from baseline itch-NRS reported 94.74 91.43% 8 16. Regarding upadacitinib, 26.32% experienced one adverse event (AE), total 13 AEs recorded, including blood test abnormalities papulopustular acne. None our interrupted drug because AE. observed higher rates EASI75/EASI90/EASI100 compared with trials. profile favorable, as no leading discontinuation